Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?

FHLC is presented as the better long-term healthcare ETF choice, charging a 0.08% expense ratio versus 0.55% for biotech-focused FBT while holding 365 companies versus 30. FBT delivered stronger trailing returns of 59.2% over one year and grew $1,000 to $1,588 over five years, compared with FHLC's 29.2% and $1,331, but suffered a deeper five-year maximum drawdown of 29.9% versus 17.7%. The article favors FHLC's diversified, lower-volatility exposure for most investors, while positioning FBT as a higher-risk vehicle for investors bullish on biotech momentum, M&A, and drug-development catalysts.

Analysis

The relevant distinction is factor exposure, not simply “diversified versus growth.” FHLC is materially exposed to large-cap pharma earnings durability and, through LLY, carries meaningful single-name GLP-1 concentration; it will not behave like a pure defensive-healthcare allocation if obesity-drug pricing, supply, or competitive assumptions reset. FBT is more directly levered to small/mid-cap biotech risk appetite, clinical readouts, and takeout premiums—factors that can reverse quickly when rates rise or large-pharma business-development budgets slow.

The recent biotech return profile likely embeds a meaningful M&A/approval premium. Acquirers face a different calculus: higher target valuations dilute deal economics, while patent-cliff urgency supports selective demand for derisked assets rather than indiscriminate buying of early-stage platforms. That favors companies with commercially validated assets or late-stage data and penalizes the broad speculative tail; FBT’s concentration makes idiosyncratic trial failures more consequential than its historical beta suggests.

There is no catalyst in this comparison alone warranting a fresh directional ETF trade. Over the next 1-3 months, watch biopharma deal announcements, FDA decision calendars, long-duration real yields, and LLY obesity-drug guidance. Over 6-18 months, FHLC should be relatively better positioned if biotech M&A multiples compress, but its downside protection is weakened if GLP-1 price competition or U.S. drug-pricing policy pressures large-pharma margins. The article’s characterization of FBT weighting should be independently verified against current holdings before using it for concentration or event-risk modeling.

Key Decisions for Investors

• No new standalone position based on this article; treat it as a monitoring item rather than a tradable catalyst.
• For healthcare exposure over the next 6-18 months, prefer FHLC over FBT only if seeking lower-volatility large-pharma exposure; cap effective LLY exposure across portfolios, since FHLC adds indirect GLP-1 concentration rather than diversifying it.
• Use a tactical long FHLC / short FBT relative-value position only after confirmation that biotech M&A activity or FDA outcomes are decelerating; target a 5-8% relative move over 1-3 months, with a stop if FBT outperforms FHLC by 5% following a renewed large-cap pharma acquisition wave.
• For existing FBT exposure, hedge event risk around major FDA or trial dates through position reduction rather than broad healthcare shorts; the appropriate hedge is biotech-specific because JNJ, ABBV, and LLY can remain resilient while small-cap biotech derates.
• Set alerts for upward real-rate breaks and any reduction in LLY obesity-drug revenue guidance: either would challenge the respective valuation supports for FBT’s long-duration biotech holdings and FHLC’s largest growth-sensitive constituent.